Rice Hall James & Associates’s Viridian Therapeutics VRDN Stock Holding History

Rice Hall James & Associates’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.6M	Buy	1,175,906 +277,295	+31%	+$4.47M	1.05%	29
2026 Q1	$17.6M	Buy	898,611 +14,079	+2%	+$418K	0.98%	31
2025 Q4	$27.5M	Buy	884,532 +32,869	+4%	+$901K	1.52%	16
2025 Q3	$18.4M	Buy	851,663 +336,040	+65%	+$6.06M	1%	30
2025 Q2	$7.21M	Buy	515,623 +152,730	+42%	+$2.07M	0.39%	66
2025 Q1	$4.89M	Buy	362,893 +309,518	+580%	+$5.27M	0.29%	77
2024 Q4	$1.02M	Buy	+53,375	New	+$1.16M	0.06%	204

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Rice Hall James & Associates's VRDN Position: Q2 2026 in Review

Rice Hall James & Associates increased its Viridian Therapeutics (VRDN) stake by 31% in Q2 2026, buying an estimated $4.47M and bringing the position to 1,175,906 shares worth $21.6M. The position accounts for 1.05% of the portfolio, ranked #29.

Rice Hall James & Associates first reported a position in VRDN in Q4 2024 and has held it in 7 quarters since. The position peaked at $27.5M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Rice Hall James & Associates held 1,175,906 shares of Viridian Therapeutics worth $21.6M as of Q2 2026.
Rice Hall James & Associates bought 277,295 Viridian Therapeutics shares in Q2 2026, an estimated $4.47M.
Viridian Therapeutics made up 1.05% of Rice Hall James & Associates's portfolio in Q2 2026, its #29 holding.
Rice Hall James & Associates first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 7 quarters since.
Rice Hall James & Associates's Viridian Therapeutics position peaked at $27.5M in Q4 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.